Dexlansoprazole

Definition

The R-isomer of lansoprazole and a substituted benzimidazole prodrug with selective and irreversible proton pump inhibitor activity. As a weak base, dexlansoprazole accumulates in the acidic environment of the secretory canaliculus of the gastric parietal cell where it is converted to an active sulfenamide form that binds to cysteine sulfhydryl groups on the luminal aspect of the proton pump hydrogen-potassium adenosine triphosphatase (H+/K+ ATPase), thereby inhibiting the pump's activity and the parietal cell secretion of H+ ions into the gastric lumen, the final step in gastric acid production.

Also known as (+)-2-((R)-{(3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methyl}sulfinyl)-1H-benzimidazole, DEXLANSOPRAZOLE, Kapidex, T-168390, TAK-390MR — per NCIT

Also identified as

• ATC A02BC06 per RXNORM
• NCIT NCIT:C73192 per NCIT
• SCTID 441863009 per RXNORM
• SCTID 442540007 per RXNORM
• UNII UYE4T5I70X per RXNORM

Indications

Organ Effects

2 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.